Integr Cancer Ther. 2016 Dec 1:1534735416681642. doi: 10.1177/1534735416681642. [Epub ahead of print]
Rojas Rojas T1,
Bourdy G2,
Ruiz E3,
Cerapio JP4,
Pineau P5,6,
Gardon J7,
Doimi F3,
Deparis X1,
Deharo E2,
Bertani S2.
- 1
- 1 Aix-Marseille Université, IRD, INSERM, UMR 912, Marseille, France.
- 2
- 2 Université de Toulouse, IRD, UPS, UMR 152, Toulouse, France.
- 3
- 3 Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
- 4
- 4 Sorbonne Universités, UPMC Univ Paris 06, Institut Pasteur, Paris, France.
- 5
- 5 Institut Pasteur, Paris, France.
- 6
- 6 INSERM, U 993, Paris, France.
- 7
- 7 Université de Montpellier, IRD, CNRS, UMR 5569, Montpellier, France.
Abstract
RATIONALE:
The highest burden of liver cancer occurs in developing countries, where the use of herbal medicine (HM) is still widespread. Despite this trend, few studies have been conducted to report HM practices of patients with a hepatic tumor in the developing world. Hence, this study aimed to document the use of HM among patients with liver cancer in Peru.
STUDY DESIGN AND METHODS:
A comparative behavioral epidemiological survey was conducted among liver cancer patients attending the National Cancer Institute of Peru. Information was obtained by direct interviews based on a semistructured questionnaire. The use of HM in Peruvian liver cancer patients was reported, first, regarding general consumption prior to the onset of disease, and second, after the appearance of symptoms that patients would relate to their tumor. In parallel, general consumption of HM in noncancerous people was assessed as a comparative figure. A correspondence analysis was performed to reveal potential associations between the symptoms of cancer and the specific use of HM.
RESULTS:
Eighty-eight patients and 117 noncancerous individuals participated in the survey. Overall, 68.3% of the people interviewed claimed to use HM on a regular basis for general health preservation. Furthermore, 56.8% of the patients turned to plants first to treat the disorders for which they later came to the cancer care center. When compared with the number of plant species used routinely (n = 78), a selection of plants was made by patients in response to the symptoms of cancer (n = 46). At least 2 plant species, Aloe vera and Morinda citrifolia, were significantly associated with the treatment of liver cancer-related symptoms in the patient group.
CONCLUSIONS:
The present study is the first survey on the HM practices of patients with liver cancer in Latin America and, more broadly, in the developing world. Our findings confirm that HM remains one of the principal primary health care resources in Peru, even for a severe disease like liver cancer. These traditional, complementary and alternative medicine practices should be taken into consideration in Peruvian health programs aiming to educate the population in cancer prevention and treatment, as well as integrative cancer management.
KEYWORDS:
Indigenous people; Latin America; behavioral epidemiological survey; cancer; complementary and alternative medicine; developing world; ethnobotany; integrative medicine; liver disease; traditional medicine
